Areva P0015

Areva P0015 is an injectable small molecule drug candidate currently in development by Areva Pharmaceuticals. It is identified in the company's pipeline as a "second market entry" product, with an expected regulatory milestone or market entry projected for 2027. Although the specific therapeutic indication and molecular target have not been publicly disclosed, the product is part of Areva's focus on injectable pharmaceuticals for oncology and supportive care. The company's documentation mentions a Biologics License Application (BLA) pathway, which is unusual for a small molecule and may suggest a complex regulatory route or a biosimilar candidate.